Curated News
By: NewsRamp Editorial Staff
August 05, 2026
VolitionRx Unveils Breakthrough Liquid Biopsy Tech with 99% Pure ctDNA
TLDR
- VolitionRx's new ctDNA technology targets $36B market, offering a competitive edge in cancer detection.
- VolitionRx's Capture-Seq uses two-step enrichment and bioinformatic filtering to isolate >99% pure ctDNA.
- This breakthrough enables earlier cancer detection, potentially saving lives and improving patient quality of life.
- VolitionRx's technology can isolate pure cancer DNA from blood, a feat previously difficult, aiding early diagnosis.
Impact - Why it Matters
This news matters because it represents a significant advancement in liquid biopsy technology, potentially enabling earlier and more accurate cancer detection and monitoring. If validated in larger studies, Volition's Capture-Seq could lead to non-invasive blood tests that detect multiple cancer types at early stages, improving patient outcomes and reducing healthcare costs. The technology also has implications for minimal residual disease monitoring, which could help guide treatment decisions and detect recurrence earlier. For investors, the potential market opportunities are substantial, with estimates of $23 billion for multi-cancer early detection and $13 billion for minimal residual disease applications. This development could disrupt the current diagnostic landscape and offer new hope for cancer patients worldwide.
Summary
VolitionRx Limited (NYSE American: VNRX) has announced the publication of the first peer-reviewed paper detailing its proprietary Capture-Seq liquid biopsy technology, which the company says is the first to isolate and analyze more than 99% pure circulating tumor-derived DNA (ctDNA). This breakthrough addresses a longstanding challenge in liquid biopsy by separating cancer-derived DNA from the large background of healthy cell-free DNA, creating highly enriched tumor DNA datasets for cancer detection and monitoring. The company is conducting technical evaluations with potential licensing partners and estimates the technology addresses annual market opportunities of approximately $23 billion for multi-cancer early detection and more than $13 billion for minimal residual disease applications.
The published research describes a two-step process combining physical sample enrichment with bioinformatic filtering to produce greater than 99% pure ctDNA sequencing datasets. Early validation studies demonstrated strong cancer detection results, including no false positives in initial cohorts and high detection rates for early-stage cancers, while additional blinded studies have produced encouraging findings. Volition is advancing larger validation studies, working with oncology key opinion leaders, and expanding patent protection as it explores commercialization opportunities. For more details, visit the full press release at https://ibn.fm/nuJEs.
Volition is a multi-national company focused on advancing the science of epigenetics, dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection and monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. This news was distributed by BioMedWire, a specialized communications platform focusing on the latest developments in the biotechnology and life sciences sectors, and is part of the Dynamic Brand Portfolio @ IBN.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, VolitionRx Unveils Breakthrough Liquid Biopsy Tech with 99% Pure ctDNA
